Neuburgh Advisers’s Theravance Biopharma TBPH Stock Holding History

Neuburgh Advisers’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$31K	Buy	1,584 +1,100	+227%	+$22.2K	﹤0.01%	862
2019 Q2	$8K	Hold	484	–	–	﹤0.01%	905
2019 Q1	$11K	Hold	484	–	–	﹤0.01%	900
2018 Q4	$12K	Buy	+484	New	+$13.1K	﹤0.01%	880

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Neuburgh Advisers's TBPH Position: Q3 2019 in Review

Neuburgh Advisers increased its Theravance Biopharma (TBPH) stake by 227% in Q3 2019, buying an estimated $22.2K and bringing the position to 1,584 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #862.

Neuburgh Advisers first reported a position in TBPH in Q4 2018 and has held it in 4 quarters since. 92 funds tracked by Wall St. Rank hold TBPH as of Q3 2019.

Neuburgh Advisers held 1,584 shares of Theravance Biopharma worth $31K as of Q3 2019.
Neuburgh Advisers bought 1,100 Theravance Biopharma shares in Q3 2019, an estimated $22.2K.
Theravance Biopharma made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #862 holding.
Neuburgh Advisers first reported a position in Theravance Biopharma in Q4 2018 and has held it in 4 quarters since.
92 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.